Skip to main content

Shakil Ian's Form 4 filing

Augmedix, Inc. (AUGX) · filed Apr 9, 2024

Accession no.
0001213900-24-031700
Filed
Apr 9, 2024
Trade date
Apr 5-8, 2024
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $357.1K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Shakil IanCIK 0001826129Director, Officer (CHIEF STRATEGY OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 5, 2024Common StockSSaleDisposed−51,387$4.03F2−$207,089.6112,217Direct
Apr 8, 2024Common StockMOption exerciseAcquired+28,563$0.64+$18,280.3240,780Direct
Apr 8, 2024Common StockSSaleDisposed−28,563$3.97−$113,395.1112,217Direct
Apr 8, 2024Common StockSSaleDisposed−9,217$3.97−$36,591.493,000Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Apr 8, 2024Common StockMOption exerciseDisposed−28,563$0.00$014,356Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

This transaction was executed in multiple trades ranging from $3.9400 to $4.1700. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)